Rgenix

23 articles with Rgenix

• RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting

  6/22/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract, “In Vivo Safety and Efficacy of RGX-019, a MerTK Targeting Monoclonal Antibody” was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting

• RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting

  6/22/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors”

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial

  5/29/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting data showing clinical activity in patients with advanced colorectal (CRC) tumors from a clinical trial of RGX-202, a first-in-class small molecule that inhibits a novel canc

• 

  AACR Annual Meeting News: Merck, RGENIX, Verastem and More

  4/29/2020

  In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.

• RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting

  4/27/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR); Initial results from the phase 1b RGX-104 plus Docetaxel combination dose escalation cohorts” was accepte

• Rgenix Names Industry Veteran to Chief Medical Officer Role

  9/16/2019

  Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry

• Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting

  4/3/2019

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting pre-clinical data from ongoing research of RGX-019,

• Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting

  4/1/2019

  Rgenix, Inc. announced that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting.

• 

  BioSpace Movers and Shakers for Dec. 3

  12/3/2018

  Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.

• Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors

  11/27/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced the appointment of Peter Van Vlasselaer, Ph.D., to its Board of Directors.

• Rgenix Treats First Patient in Phase 1 Trial of RGX-202

  10/31/2018

  Rgenix, Inc. today announced it has treated the first patient in a Phase 1 a/b study of RGX-202.

• Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs

  10/9/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced that it has raised $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs

• Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting

  6/4/2018

  RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab.

• Rgenix to Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting

  5/31/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5.

• 

  AACR Meeting Brief: Sosei, Verseon, Rgenix, Xencor and others

  4/18/2018

  The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.

• Rgenix Presents Pre-Clinical Data on RGX-202 at the 2018 AACR Annual Meeting

  4/18/2018

  Pre-clinical data indicates RGX-202 suppresses cancer growth in colon and pancreatic cancer models Rgenix plans to initiate a clinical study of RGX-202 in patients with advanced gastrointestinal malignancies

• Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity

  1/12/2018

  Rgenix announced today the publication of clinical and pre-clinical results by research collaborators at Rgenix and The Rockefeller University.

• Rgenix Appoints Chief Medical Officer

  4/28/2017